Hwang, Liang-EnLiang-EnHwangKUAN-YIN LINPING-HUEI TSENGHo, Shu-YuanShu-YuanHoCHUN-YI LUSHAO-YI CHENGMING-JU HSIEHYU-TSUNG HUANGChien, Shu-FenShu-FenChienSu, Chi-HsuanChi-HsuanSuSUNG-CHING PANHAN-MO CHIUYEE-CHUN CHENSHAN-CHWEN CHANG2025-11-022025-11-022025-10-03https://scholars.lib.ntu.edu.tw/handle/123456789/733349Introduction: The study aimed to assess the effects of a single-dose measles, mumps, and rubella (MMR) booster vaccination, without prior testing, on MMR immunity and infection among vulnerable healthcare personnel (HCP) 10 years after implementation in a highly vaccinated population. Methods: We conducted a single-center, cross-sectional study to assess the MMR seroprevalence in HCP and health examinees enrolled from December 2021 through April 2023. Since 2013, the hospital has provided a single-dose MMR booster vaccine to HCP working in high-risk units and those born in or after 1981 (≤41 years of age). HCP who met the Taiwan CDC's operational criteria for measles immunity were exempted. MMR-specific IgG antibodies were measured, and detailed vaccination histories were obtained. Results: A total of 732 participants were enrolled, including 528 HCP and 204 health examinees. The median age was 43 years, and 74.6 % were female. The overall seroprevalence rates of measles, mumps, and rubella were 89.8 %, 91.0 % and 88.0 %, respectively. The measles seroprevalence rate was lowest among participants aged 31–40 years (80.4 % in HCP and 82.4 % in health examinees). In multivariable analysis, age was associated with measles seropositivity (per 1-year increase, aOR, 1.08; 95 % CI 1.04–1.12). Receiving MMR booster vaccination in adulthood was associated with seropositivity for measles (aOR, 2.77; 95 % CI, 1.46–5.24) and mumps (aOR, 2.39; 95 % CI, 1.23–4.65). No cases of measles acquisition or intra-hospital spread were identified among HCP during the past 10 years. Conclusions: An MMR booster vaccination program is feasible and effective in maintaining high seropositivity rates for MMR, particularly among HCP at risk of waning immunity.enAdult vaccinationHospital vaccination programOccupation safetySeroprevalenceVaccine-preventable diseaseWaning immunity[SDGs]SDG3journal article10.1016/j.vaccine.2025.12775840992077